PMID: 6989067Mar 1, 1980Paper

Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study

Tubercle
M Zierski, E Bek

Abstract

An analysis is presented of the side effects which occurred in 530 patients treated with 6 months chemotherapy for newly detected pulmonary tuberculosis. Five treatment regimens were used. The initial phase of treatment consisted of daily isoniazid, rifampicin and ethambutol (HRE) or isoniazid, rifampicin, streptomycin and pyrazinamide (HRSZ) given for 2 months. The second phase of treatment consisted of isoniazid and rifampicin given twice weekly (H2R2) or isoniazid, rifampicin and ethambutol given daily (4HRE) or intermittently (H1R1E1 or H2R2E2) for 4 months. Side effects were detected in 66 (12.4%) patients. Hepatotoxic reactions occurred in 48 (9%) patients, mainly of amild and transient nature and the majority were attributable to isoniazid. The 'flu like' syndrome occurred in only 2 patients both during the daily phase of treatment, and it was not encountered in patients taking rifampicin intermittently (dose 600 mg). Inclusion of pyrazinamide in the initial phase of 1 regimen did not result in an increase of frequency of side effects. In 56% of patients on pyrazinamide the serum uric acid concentration was elevated but there was no arthralgia. Drug toxicity leading to alteration or withdrawal of treatment occurred in on...Continue Reading

Citations

Mar 4, 2000·Advanced Drug Delivery Reviews·A K Agrawal, C M Gupta
May 5, 2010·Antimicrobial Agents and Chemotherapy·Jotam G Pasipanodya, Tawanda Gumbo
Jan 1, 1991·Antimicrobial Agents and Chemotherapy·S Majumdar, S K Basu
Mar 1, 1994·Antimicrobial Agents and Chemotherapy·A AgarwalC M Gupta
Oct 24, 2001·American Journal of Respiratory and Critical Care Medicine·W J Burman, R R Reves
May 11, 2004·American Journal of Respiratory and Critical Care Medicine·Chi Chiu LeungWing Wai Yew
Feb 18, 2003·American Journal of Respiratory and Critical Care Medicine·Henry M BlumbergUNKNOWN American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society
Feb 6, 2003·American Journal of Respiratory and Critical Care Medicine·Daphne YeeDick Menzies
Oct 6, 2006·American Journal of Respiratory and Critical Care Medicine·Jussi J SaukkonenUNKNOWN ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee
Jul 16, 2013·New South Wales Public Health Bulletin·David Michail
Sep 22, 2009·Enfermedades infecciosas y microbiología clínica·Pere Coll
Jun 1, 1987·Tubercle·P HerlevsenJ T Pedersen
Apr 1, 1993·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A JainS Kulshrestha
Jun 25, 1998·American Journal of Infection Control·T F BrewerM Ettling
Apr 20, 2005·Clinics in Chest Medicine·Behzad Sahbazian, Stephen E Weis
Jan 16, 2010·Journal of Evaluation in Clinical Practice·Jef Van den EndeMarleen Boelaert
Mar 1, 2006·Expert Opinion on Drug Safety·Eric J Forget, Dick Menzies
Feb 1, 1991·Chest·M A SteeleR M DesPrez
Aug 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Oct 1, 1988·Chest·M A Steele, R M Des Prez
Sep 14, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Payam NahidAndrew Vernon
Sep 1, 1985·Journal of Clinical and Hospital Pharmacy·S R SmithR A Stockley
Sep 1, 1988·Tubercle·V K JainO M Prakash
Jan 24, 2007·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Paulin BasingaJef Van den Ende
Sep 3, 2016·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
Aug 16, 2006·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
Jun 23, 2009·American Journal of Respiratory and Critical Care Medicine·John L JohnsonW Henry Boom
Oct 7, 2018·BMC Infectious Diseases·Liesbeth F MierasMarieke G G Sturkenboom

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.